Recombinant Protein Pharmacovigilance: Deployment and

Data Characteristics

Recombinant protein pharmacovigilance data originates from clinical trial reports, real-world studies, post-market surveillance reports, medical literature, and regulatory databases. This data exists in both structured (e.g., electronic health record systems, adverse event report forms) and unstructured (e.g., clinician notes, patient interview records) formats. Update frequency varies: clinical trial data typically updates periodically during trials, while post-market surveillance data may aggregate in real-time or near real-time. Document structures are complex, including basic drug information, patient demographics, adverse event descriptions (onset time, severity, outcome), relevant laboratory test results, and concomitant medication details. Fields may include ICD-10 codes, MedDRA terms, drug batch numbers, dosage units (e.g., mg/kg, IU), administration routes, and specific adverse event descriptions.

Constraints on Deployment and Upgrade

The coexistence of highly structured and unstructured recombinant protein drug data poses challenges for data preprocessing and knowledge base construction. Deployment requires effective integration of data from diverse sources and formats, ensuring data quality and consistency. For example, the real-time nature of post-market surveillance demands rapid knowledge base updates to reflect the latest safety information. Medical terminology, abbreviations, and contextual dependencies in unstructured text necessitate robust natural language processing capabilities for semantic extraction and standardization. During upgrades, historical data compatibility is a critical consideration. When medical terminology versions like MedDRA update, ensure old data maps correctly to new versions to prevent information loss or misinterpretation. The precision required for recombinant protein drug dosages and administration routes demands careful handling of numerical fields in configuration parameters, ensuring accurate unit conversions.

Configuration Settings

Configuration Item	Recommended Value	Rationale
`maxContext`	`3000 Tokens`	Covers the typical information volume in recombinant protein drug adverse reaction reports.
`PARSE_FILE_TIMEOUT_SECONDS`	`600 seconds`	Accommodates parsing time for large clinical trial reports or complex medical literature.
`Chunk size` (Segment Length)	`800–1200 characters`	Balances contextual completeness and retrieval efficiency, ensuring adverse event descriptions are not fragmented.
`Recall count` (Recall Count)	`Top 8`	Covers multiple potentially relevant adverse event reports or literature snippets.
`Similarity threshold` (Similarity Threshold)	`0.75`	Filters for highly relevant recombinant protein drug adverse reaction information.
`Rerank result count` (Rerank Return Count)	`Top 5`	Refines final results, focusing on the most critical pharmacovigilance information.

Common Pitfalls

Knowledge base queries return a large amount of irrelevant information. This may be due to a Similarity threshold (Similarity Threshold) set too low, recalling general adverse reactions inconsistent with recombinant protein drug characteristics.
When importing historical data, some adverse event description fields are empty. This may be because medical terms in older data versions were not effectively mapped to new MedDRA terms, or data cleaning scripts failed to correctly process non-standard formats.
Workflow orchestration errors occur after an upgrade, manifesting as a 500 Internal Server Error. This may be due to specific nodes or parameters in older workflows (e.g., v4.6.7) being modified or deprecated in newer versions (e.g., v4.8.10), leading to compatibility issues.

Verification Steps

Select test data containing typical recombinant protein drug adverse events. Simulate user queries and check if recall results accurately cover key information, such as drug names, adverse event types, and severity.
Import a batch of recombinant protein drug-related documents in various formats (PDF, DOCX, TXT). Observe if all documents complete parsing within the specified PARSE_FILE_TIMEOUT_SECONDS and verify the parsed text content is complete and accurate.
After an upgrade, run a regression test suite covering various data types and query scenarios. Verify that knowledge base and workflow outputs align with expected results, paying close attention to correct identification and matching of MedDRA terms.

Note: The values provided are common starting points. Measure against specific samples.

Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.